LMS and Impli Launch €6M International Challenge to Revolutionize Hormone Monitoring with BEAM Biosensor Platform for Simultaneous 5-Hormone Measurement

September 20, 2026

MRC Laboratory of Medical Sciences UK

Overview

MRC Laboratory of Medical Sciences (LMS) has partnered with technology company Impli in a €6 million international challenge to transform hormone monitoring. The program aims to extend Impli’s BEAM biosensor platform to continuously and simultaneously measure five hormones. This minimally invasive sensing technology will generate real-time data, providing researchers and clinicians with deeper insights into treatment responses, thereby accelerating personalized medicine and drug discovery.

In Depth

Key Findings

The MRC Laboratory of Medical Sciences (LMS) has announced a strategic partnership with the technology company Impli, launching a €6 million international initiative designed to fundamentally transform the field of hormone monitoring. The core objective of this collaboration is to significantly expand Impli’s innovative BEAM biosensor platform, enabling it to continuously and simultaneously measure five distinct hormones.

Technical / Clinical Details

While Impli’s BEAM biosensor platform has previously focused on individual hormone measurements, this challenge will drastically enhance its multiplexing capabilities. The minimally invasive sensing technology will allow for the high-precision, real-time detection of multiple hormone levels from minute biological samples. This continuous monitoring will capture the complex diurnal variations of hormones and their responses to therapeutic interventions, providing detailed data unattainable through conventional spot measurements. Such real-time data will empower researchers and clinicians with deeper insights for diagnosing endocrine disorders, optimizing treatment regimens, and evaluating the efficacy of novel pharmaceutical agents. Initial proof-of-concept studies demonstrated over 95% accuracy and response times within minutes for existing single-hormone measurements.

Background & Context

Hormonal balance is critically important across a wide spectrum of medical fields, including reproductive health, metabolic disorders, stress responses, and cancer therapy. However, the high variability of hormone levels and the limitations of intermittent blood sampling have made it challenging to fully understand their complex dynamics. The multiplexing and continuous monitoring capabilities of the BEAM platform are poised to bridge this gap, improving patient outcomes and driving personalized medical approaches. Furthermore, this technology is expected to aid drug discovery by enabling real-time assessment of drug mechanisms and side effects.

Strategic Significance & Outlook

This €6 million international challenge holds the potential to redefine the paradigm for diagnosing, treating, and even preventing hormone-related conditions. The successful implementation of simultaneous five-hormone monitoring would represent a major leap forward in endocrinology research and clinical practice. The LMS-Impli partnership exemplifies the synergy between academic research and industrial technology, underscoring the importance of international collaboration in the biosensor sector.

Source: https://lms.mrc.ac.uk/lms-partners-with-tech-company-impli-in-e6m-international-challenge-to-transform-hormone-monitoring/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.